Pfizer's Talzenna-Xtandi Combo Gets FDA Priority Review for Earlier-Stage Prostate Cancer
By Anvee Bhutani
Pfizer said Wednesday the Food and Drug Administration accepted for priority review its supplemental application seeking to expand the use of its prostate cancer treatment Talzenna in combination with Xtandi to patients with an earlier stage of advanced disease.
The drugmaker said the supplemental new drug application seeks approval for the combination in men with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer. The FDA set a decision date in the fourth quarter of 2026.
Talzenna plus Xtandi is already approved in the U.S. to treat men with HRR gene-mutated metastatic castration-resistant prostate cancer. If approved, the expanded label would allow the therapy to be used earlier in the course of the disease.
The filing is supported by data from the Phase 3 TALAPRO-3 trial, which showed the combination reduced the risk of radiographic disease progression or death by 52% compared with Xtandi alone. Pfizer said the benefit was consistent across patients with both BRCA and non-BRCA HRR gene alterations, with no new safety signals identified.
The application is also under review by the European Medicines Agency.
Write to Anvee Bhutani at anvee.bhutani@wsj.com
(END) Dow Jones Newswires
July 22, 2026 17:41 ET (21:41 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States